Oncology
Pancreatic Cancer Is Forcing Regulators to Move Faster
EMA has started a phased review of daraxonrasib in pancreatic cancer, while Revolution Medicines says its U.S. rolling NDA is nearing completion. The science is moving into the regulatory fast lane. Access systems are not ready yet.
The Transplant Is Not the Finish Line
Chemo Shortages Are Back. So Is Rationing.
For Cancer That Reaches the CNS, a Payer Opens a Door
Europe Opens Another Lung Cancer Door to China-Origin Immunotherapy
In Australia, Cancer Medicine Delays Cost More Than Time
BRCA Care Cannot Start at Diagnosis
The Money Is Moving Into Cancer Screening. The Evidence Still Has to Catch Up.
Europe Opens Another Lung Cancer Door to China-Origin Immunotherapy
In Australia, Cancer Medicine Delays Cost More Than Time
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.